The Swiss company was developing a fever product before the Tylenol recall but sped up its introduction to fill a void in the marketplace, a company
spokeswoman says. "If you are going to take on children's Tylenol, now is the time to do it," says Mick Kolassa, the chairman of Medical Marketing Economics. "It's a beautiful
opportunity. There's concern. There's a shortage. There's a wide opening in the marketplace."
Writing in the Wall Street Journal's "Health Blog," Katherine Hobson says the story reminds her of the Tour de France, where Alberto Contador took a stab at the lead after his rival dropped his bike chain. "That's considered unsporting -- but then," she points out, "the rules of the peloton are very different than those of the global pharma marketplace."